Terms of the Loan

The Company has entered into a bridge loan agreement in the amount of DKK 2 million with a syndicate of ten (10) investors (collectively, the "Lenders"), including JEQ Capital AB, the Company’s largest current shareholder. None of the Lenders are considered related parties to the Company under applicable regulations, and the Loan is unsecured, with no pledges or collateral provided.

The Loan carries an upfront arrangement fee of 15% of the principal amount and a recurring monthly fee of 2%, calculated on a non-compounding basis.

Pursuant to the terms of the Loan, each Lender is entitled to request conversion of their respective outstanding principal and accrued fees into shares in the Company at a conversion price equal to the volume-weighted average trading price ("VWAP") of the Company’s shares over the period immediately preceding the execution of the Loan, which is DKK 1.13 per share.

The Company retains the right to repay the Loan in full at any time, subject to a minimum written notice of ten (10) business days.

In the event that the Company initiates a capital raise prior to full repayment or conversion of the Loan, the Lenders shall be entitled to convert the outstanding Loan amount into underwriting commitments on equivalent terms as those offered to other underwriters in such offering.

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma A/S is listed on the Spotlight Stock Market in Copenhagen/Stockholm. For more information, please visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.